Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (411-420 of 740) with videos related to

Pageof 74
Sort By:
Blood|November 23, 2016
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsMaria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, et al.
The Lancet. Haematology|July 1, 2018
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart reviewChristian Buske, Shalal Sadullah, Efstathios Kastritis, et al.
Urology|January 25, 2011
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancerIoannis Mountzios, Evangelos Bournakis, Eleni Efstathiou, et al.
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Gynecologic Oncology|March 17, 2020
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapyMichalis Liontos, Maria Sotiropoulou, Maria Kaparelou, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancerTina Bagratuni, Nefeli Mavrianou, Nikolaos G Gavalas, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Blood|September 6, 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, et al.
British Journal of Haematology|February 7, 2024
Thrombotic and bleeding complications in patients with AL amyloidosisDespina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
Pageof 74

Showing results (411-420 of 740) with videos related to

Sort By:
Pageof 74
Blood|November 23, 2016
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsMaria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, et al.
The Lancet. Haematology|July 1, 2018
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart reviewChristian Buske, Shalal Sadullah, Efstathios Kastritis, et al.
Urology|January 25, 2011
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancerIoannis Mountzios, Evangelos Bournakis, Eleni Efstathiou, et al.
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Gynecologic Oncology|March 17, 2020
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapyMichalis Liontos, Maria Sotiropoulou, Maria Kaparelou, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancerTina Bagratuni, Nefeli Mavrianou, Nikolaos G Gavalas, et al.
Future Oncology (London, England)|May 10, 2025
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaSagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja, et al.
Blood|September 6, 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, et al.
British Journal of Haematology|February 7, 2024
Thrombotic and bleeding complications in patients with AL amyloidosisDespina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
Pageof 74